EX-99.1 2 ea030178701ex99-1.htm PRESS RELEASE, DATED AUGUST 13, 2026 Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Working with Suppliers to Maximize Product Shipments Through End of Fiscal Year Received ISO 13485 Certification Ahead of Schedule; International Expansion Planned StereoCED™ Drug Delivery System Expected to be Available for Research and Investigational Clinical Studies by the End of Fiscal Year 2026 Management to Host Conference Call at 8:30 a.m. Eastern Time Today EDEN PRAIRIE, Minn., August 13, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and provided a business update for the third quarter of fiscal year 2026 ended June 30, 2026. FY Q3 2026 Financial Highlights Product revenue increased 16% to $2.0 million, compared to $1.7…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
NeuroOne Medical Technologies Corporation
NMTCNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 13, 2026, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended June 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.…
Company context
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.